1. ALLA AKTIER
  2. NYHETER
  3. ABLIVA

Abliva

Nyheter Abliva Nyheter alla bolag

Abliva publishes rights issue outcome

MARKN.

THIS PRESS RELEASE IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER COUNTRY WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD VIOLATE APPLICABLE LAWS OR REGULATIONS OR WOULD REQUIRE ADDITIONAL DOCUMENTS TO BE PREPARED OR REGISTERED OR REQUIRE ANY OTHER ACTIONS TO BE TAKEN, IN ADDITION TO THE REQUIREMENTS UNDER SWEDISH LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva”) or the ”Company”) today announces that the new share issue with preferential rights for existing shareholders, announced by the Company on 22 February 2024 (the “Rights Issue”), has been completed. In the Rights Issue, 184,931,634 shares, corresponding to approximately 64.2 percent of the Rights Issue, were subscribed for with the use of subscription rights. In addition, 3,241,219 shares, corresponding to approximately 1.1 percent of the Rights Issue, were subscribed for without the use of subscription rights and 99,908,735 shares, corresponding to approximately 34.7 percent of the Rights Issue, were subscribed for by share issue guarantors. In total, the Rights Issue was subscribed to 100 percent, which implies that Abliva raises approximately SEK 46 million before deduction for transactions costs. The rights issue is part of an approximately SEK 88 million financing that also includes a directed issue of convertible bonds to a limited number of certain existing shareholders and institutional investors, provided that the result from the interim analysis, in mid-2024, is positive (non-futile).

Through the Rights Issue, Abliva raises approximately SEK 46 million before transactions costs, which are estimated to amount to approximately SEK 6.5 million. The final outcome shows that 184,931,634 shares, corresponding to approximately 64.2 percent of the Rights Issue, were subscribed for with the use of subscription rights. In addition, 3,241,219 shares, corresponding to approximately 1.1 percent of the Rights Issue, were subscribed for without the use of subscription rights and 99,908,735 shares, corresponding to approximately 34.7 percent of the Rights Issue, were subscribed for by share issue guarantors.

Through the Rights Issue, the Company’s share capital increases by SEK 14,404,079.40 from SEK 52,814,958.25 to SEK 67,219,037.65 and the number of shares increases by 288,081,588 shares from 1,056,299,165 shares to 1,344,380,753 shares.

Trading in paid subscribed shares (BTA) on Nasdaq Stockholm will continue under the short name ABLI BTA until the Rights Issue has been registered with the Swedish Companies Registration Office (Sv. Bolagsverket), which is expected to take place on or around May 8, 2024. After that, BTA will be converted into shares after approximately one week.

Allotment of shares subscribed for without the use of subscription rights has been made in accordance with the principles set out in the prospectus that has been prepared for the Rights Issue and published by the Company on 27 March 2024. Notice of allotment is provided through the distribution of a settlement note by mail to the respective subscriber. Allotted shares shall be paid for in accordance with the instructions on the settlement note.

“I would like to take this opportunity to thank everyone who participated in the rights issue. Your participation ensures that we can continue our work in the KL1333 program while we carry out the interim analysis. In addition, this financing will allow us to prepare for the final stage of the FALCON study while providing additional runway to discuss the program with potential partners and investors”, said Ellen Donnelly, CEO of Abliva AB.

Holders of convertible bonds shall convert the entirety of the loan amount within five banking days from the time at which the Company announces the interim data from the KL1333 Phase 2 study, estimated in mid-2024, if it results in a positive, i.e. non futile, outcome.

Advisors
Hagberg & Aneborn Fondkommission AB is the sole global coordinator and bookrunner in connection with the Rights Issue. Cirio Advokatbyrå AB is legal advisor to Abliva in connection with the Rights Issue.

For more information, please contact:

Catharina Johansson, Deputy CEO, CFO & VP Investor Relations
+46 (0)46-275 62 21, ir@abliva.com

Abliva AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
info@abliva.com, www.abliva.com

Subscribe to our news: https://abliva.com/posts/news-subscription/
Follow us on LinkedIn: https://www.linkedin.com/company/abliva
Subscribe to our YouTube channel: https://www.youtube.com/channel/UChqP7Ky5caXtp72CELhD6Mg

Abliva – Delivering mitochondrial health

Abliva discovers and develops medicines for the treatment of mitochondrial disease. This rare and often very severe disease occurs when the cell’s energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, has entered late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

Important information

Release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions according to law and persons in those jurisdictions, in which this press release has been announced or distributed, should inform themselves of and follow such legal restrictions. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Abliva in any jurisdiction.
 
This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended. The information in this press release may not be announced, published or distributed to Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, Switzerland, the United States, or in any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations.

This press release is not a prospectus.

Attachments

Abliva publishes rights issue outcome

Datum 2024-04-19, kl 15:40
Källa MFN
Bifogade filer
Abliva publishes rights issue outcome
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!